OpenClinical trial: Optional / allowed
Eisai Investigator-Initiated Studies (IIS)
Eisai · Industry
Source: Eisai (curated) · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- Amount not listed
- DeadlineFinal application due date.
- Rolling — apply anytime
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- —
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Rolling
- Open dateWhen applications open (or opened).
- —
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- —
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Optional / allowed
Established investigatorHigher education
Research areas
Therapeutics & drug discoveryClinical trials
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Investigator-initiated studies across Eisai's therapeutic portfolio (oncology and neurology, including Alzheimer's — Eisai markets Leqembi/lecanemab). Rolling intake through a gated company portal; funding and/or study drug. Directory entry — verify scope/fit at the portal.
This funder has no public API, so the entry is manually curated — confirm current amounts, deadlines, and eligibility on the source page.